Processa Pharmaceuticals Q3 2026 Results: Net Loss of $183M, Loss Widens
Processa Pharmaceuticals reported a significant net loss of $189.8 million for the nine months ended September 30, 2026, primarily driven by a $178.0 million charge for acquired in-process research and development following the acquisition of Vidya Therapeutics. The company significantly strengthened its liquidity position during the period, ending with $180.2 million in cash and cash equivalents following a $200.0 million private placement financing.
- Key figure
- Net loss $183M